ASPIRE BIOPHARMA HOLDINGS, INC. Research and Development Expense
ASPIRE BIOPHARMA HOLDINGS, INC. (ASBP) reported Research and Development Expense of $233.48 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- ASPIRE BIOPHARMA HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $233.48K, a 33.84% decline year-over-year.
- ASPIRE BIOPHARMA HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $296.72K, a 12.78% increase year-over-year.
- ASPIRE BIOPHARMA HOLDINGS, INC. research and development expense for the quarter ending 2025-12-31 was $100.03K, a 14.03% decline year-over-year.
- ASPIRE BIOPHARMA HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $207.90K, a 2869.99% increase year-over-year.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $233.48K 10-Q · filed 2026-08-13 | $530.21K 10-Q · filed 2026-08-13 | $630.24K derived: sum of 3 quarters · filed 2026-08-13 | $838.14K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $296.72K 10-Q · filed 2026-05-15 | $396.76K derived: sum of 2 quarters · filed 2026-05-15 | $604.66K derived: sum of 3 quarters · filed 2026-05-15 | $957.54K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $100.03K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-04-10 | $307.93K derived: sum of 2 quarters · filed 2026-04-10 | $660.82K derived: sum of 3 quarters · filed 2026-08-13 | $923.91K S-1/A · filed 2026-04-10 |
| 2025-09-30 | $207.90K 10-Q · filed 2025-11-14 | $560.79K derived: sum of 2 quarters · filed 2026-08-13 | $823.88K 10-Q · filed 2025-11-14 | $940.24K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $352.89K 10-Q · filed 2026-08-13 | $615.98K 10-Q · filed 2026-08-13 | $732.34K derived: sum of 3 quarters · filed 2026-08-13 | $739.34K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $263.09K 10-Q · filed 2026-05-15 | $379.45K derived: sum of 2 quarters · filed 2026-05-15 | $386.45K derived: sum of 3 quarters · filed 2026-05-15 | $396.95K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $116.36K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-04-10 | $123.36K derived: sum of 2 quarters · filed 2026-04-10 | $133.86K derived: sum of 3 quarters · filed 2026-04-10 | $144.36K S-1/A · filed 2026-04-10 |
| 2024-09-30 | $7.00K 10-Q · filed 2025-11-14 | $17.50K derived: sum of 2 quarters · filed 2025-11-14 | $28.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $10.50K 10-Q · filed 2025-08-13 | $21.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $10.50K 10-Q/A · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |